Cecile V. Denis

Cecile V. Denis

Auto-generated profile, based on publicly available information

Cecile V. Denis

HITh, UMR_S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2002 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PAPatrick André
Patrick André
KPK.S. Srinivasa Prasad
K.S. Srinivasa Prasad
CDCécile V. Denis
Cécile V. Denis
MHMing He
Ming He
JPJessie M. Papalia
Jessie M. Papalia
DWDenisa D. Wagner
Denisa D. Wagner

4 August 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CDCécile Denis
Cécile Denis
NMNassia Methia
Nassia Methia
PFPaul S. Frenette
Paul S. Frenette
HRHelen Rayburn
Helen Rayburn
MUMollie Ullman-Culleré
Mollie Ullman-Culleré
DWDenisa D. Wagner
Denisa D. Wagner
Von Willebrand factor (vWf) deficiency causes severe von Willebrand disease in humans. We generated a mouse model for this disease by using gene targeting. vWf-deficient mice appeared normal at birth; they were viable and fertile. Neither vWf nor vWf propolypeptide (von Willebrand antigen II) were detectable in plasma, platelets, or endothelial cells of the homozygous mutant mice. The mutant mice exhibited defects in hemostasis with a highly prolonged bleeding time and spontaneous bleeding events in ≈10% of neonates. As in the human disease, the factor VIII level in these mice was reduced strongly as a result of the lack of protection provided by vWf. Defective thrombosis in mutant mice was also evident in an in vivo model of vascular injury. In this model, the exteriorized mesentery was superfused with ferric chloride and the accumulation of fluorescently labeled platelets was observed by intravital microscopy. We conclude that these mice very closely mimic severe human von Willebrand disease and will be very useful for investigating the role of vWf in normal physiology and in disease models.

1 August 2000 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
HNHeyu Ni
Heyu Ni
CDCécile V. Denis
Cécile V. Denis
SSSangeetha Subbarao
Sangeetha Subbarao
JDJay L. Degen
Jay L. Degen
TSThomas N. Sato
Thomas N. Sato
DWDenisa D. Wagner
Denisa D. Wagner
We used intravital microscopy to observe the formation of platelet plugs in ferric chloride–injured arterioles of live mice. With this model, we evaluated thrombus growth in mice lacking von Willebrand factor (vWF) and fibrinogen (Fg), the two key ligands known to mediate platelet adhesion and aggregation. In vWF–/– mice, despite the presence of arterial shear, delayed platelet adhesion occurred and stable thrombi formed. In many mice, a persisting high-shear channel never occluded. Abundant thrombi formed in Fg–/– mice, but they detached from the subendothelium, which ultimately caused downstream occlusion in all cases. Surprisingly, mice deficient in both vWF and Fg successfully formed thrombi with properties characteristic of both mutations, leading to vessel occlusion in the majority of vessels. Platelets of these doubly deficient mice specifically accumulated fibronectin in their α-granules, suggesting that fibronectin could be the ligand supporting the platelet aggregation.

26 March 2015 in Blood
Verified
Journal Article
Open access
PDF file
PLPeter J. Lenting
Peter J. Lenting
OCOlivier Christophe
Olivier Christophe
CDCécile V. Denis
Cécile V. Denis
To understand the placement of a certain protein in a physiological system and the pathogenesis of related disorders, it is not only of interest to determine its function but also important to describe the sequential steps in its life cycle, from synthesis to secretion and ultimately its clearance. von Willebrand factor (VWF) is a particularly intriguing case in this regard because of its important auxiliary roles (both intra- and extracellular) that implicate a wide range of other proteins: its presence is required for the formation and regulated release of endothelial storage organelles, the Weibel-Palade bodies (WPBs), whereas VWF is also a key determinant in the clearance of coagulation factor VIII. Thus, understanding the molecular and cellular basis of the VWF life cycle will help us gain insight into the pathogenesis of von Willebrand disease, design alternative treatment options to prolong the factor VIII half-life, and delineate the role of VWF and coresidents of the WPBs in the prothrombotic and proinflammatory response of endothelial cells. In this review, an update on our current knowledge on VWF biosynthesis, secretion, and clearance is provided and we will discuss how they can be affected by the presence of protein defects.

1 January 2003 in Cell
Verified
Journal Article
Closed access
KHKarin M. Hoffmeister
Karin M. Hoffmeister
TFThomas W. Felbinger
Thomas W. Felbinger
HFHervé Falet
Hervé Falet
CDCécile V. Denis
Cécile V. Denis
WBWolfgang Bergmeier
Wolfgang Bergmeier
JHJohn H. Hartwig
John H. Hartwig

17 April 2000 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
PFPaul S. Frenette
Paul S. Frenette
CDCécile V. Denis
Cécile V. Denis
LWLinnea Weiss
Linnea Weiss
KJKerstin Jurk
Kerstin Jurk
SSSangeetha Subbarao
Sangeetha Subbarao
DWDenisa D. Wagner
Denisa D. Wagner
The platelet plays a pivotal role in maintaining vascular integrity. In a manner similar to leukocytes, platelets interact with selectins expressed on activated endothelium. P-selectin glycoprotein ligand 1 (PSGL-1) is the main P-selectin ligand expressed on leukocytes. Searching for platelet ligand(s), we used a P-selectin–immunoglobulin G (IgG) chimera to affinity purify surface-biotinylated proteins from platelet lysates. P-selectin–bound ligands were eluted with ethylenediaminetetraacetic acid. An ∼210-kD biotinylated protein was isolated from both human neutrophil and platelet preparations. A band of the same size was also immunopurified from human platelets using a monoclonal anti–human PSGL-1 antibody and could be blotted with P-selectin–IgG. Under reducing conditions, both the predicted PSGL-1 ∼210-kD dimer and the ∼120-kD monomer were isolated from platelets. Comparative immunoelectron microscopy and Western blotting experiments suggested that platelet PSGL-1 expression is 25–100-fold lower than that of leukocytes. However, patients with chronic idiopathic thrombocytopenic purpura who harbor predominantly young platelets displayed greater expression, indicating that PSGL-1 expression may be decreased during platelet aging. By flow cytometry, thrombin-activated platelets from normal individuals exhibited greater expression than those unstimulated. An inhibitory anti–PSGL-1 antibody significantly reduced platelet rolling in mesenteric venules, as observed by intravital microscopy. Our results indicate that functional PSGL-1 is expressed on platelets, and suggest an additional mechanism by which selectins and their ligands participate in inflammatory and/or hemostatic responses.